{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:41:17Z","timestamp":1793018477509,"version":"4.5.0"},"reference-count":61,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"14","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2024,12,2]]},"DOI":"10.1167\/iovs.65.14.1","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:30:55Z","timestamp":1733131855000},"page":"1","source":"Crossref","is-referenced-by-count":23,"title":["Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies"],"prefix":"10.1167","volume":"65","author":[{"given":"Melissa A.","family":"Calton","sequence":"first","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne H.","family":"Croze","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Burns","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghezal","family":"Beliakoff","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tandis","family":"Vazin","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Szymanski","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schmitt","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Klein","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Leong","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Quezada","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Holt","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe","family":"Bolender","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Barglow","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Khoday","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mason","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Delaria","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hassanipour","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kotterman","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, Nevada, United States"},{"name":"University of Nevada, Reno School of Medicine, Reno, Nevada, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schaffer","sequence":"additional","affiliation":[{"name":"University of California, Berkeley, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Francis","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kirn","sequence":"additional","affiliation":[{"name":"4D Molecular Therapeutics, Emeryville, California, United States"},{"name":"University of California, Berkeley, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","first-page":"493","article-title":"Updates on the epidemiology of age-related macular degeneration","volume":"6","author":"Jonas","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41433-020-1087-6","article-title":"Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2474126417725946","article-title":"Current best clinical practices\u2014management of neovascular AMD","volume":"1","author":"Brown","year":"2017","journal-title":"J Vitreoretin Dis"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ajo.2014.05.025","article-title":"Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration","volume":"158","author":"Fauser","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research G","year":"2011","journal-title":"N Engl J Med"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-Khersan","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/eye.2017.108","article-title":"Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK aflibercept users group","volume":"31","author":"Almuhtaseb","year":"2017","journal-title":"Eye (Lond)"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research G","year":"2016","journal-title":"Ophthalmology"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/cells8030270","article-title":"Two birds, one stone: double hits on tumor growth and lymphangiogenesis by targeting vascular endothelial growth factor receptor 3","volume":"8","author":"Hsu","year":"2019","journal-title":"Cells"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/01.RES.0000118600.91698.BB","article-title":"Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability","volume":"94","author":"Cao","year":"2004","journal-title":"Circ Res"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2147\/OPTH.S171636","article-title":"Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment","volume":"12","author":"Pongsachareonnont","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol Ther"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/mt.2011.255","article-title":"Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells","volume":"20","author":"Asuri","year":"2012","journal-title":"Mol Ther"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/mt.2010.287","article-title":"An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells","volume":"19","author":"Jang","year":"2011","journal-title":"Mol Ther"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/mt.2008.167","article-title":"DNA shuffling of adeno-associated virus yields functionally diverse viral progeny","volume":"16","author":"Koerber","year":"2008","journal-title":"Mol Ther"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/hum.2006.139","article-title":"Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography","volume":"18","author":"Koerber","year":"2007","journal-title":"Hum Gene Ther"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1038\/mt.2009.184","article-title":"Molecular evolution of adeno-associated virus for enhanced glial gene delivery","volume":"17","author":"Koerber","year":"2009","journal-title":"Mol Ther"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nprot.2006.93","article-title":"Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles","volume":"1","author":"Koerber","year":"2006","journal-title":"Nat Protoc"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat Biotechnol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/mt.2014.139","article-title":"Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants","volume":"22","author":"Marsic","year":"2014","journal-title":"Mol Ther"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/humc.2015.076","article-title":"Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin","volume":"26","author":"Ye","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1167\/iovs.10-6250","article-title":"Intravitreal injection of AAV2 transduces macaque inner retina","volume":"52","author":"Yin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1523\/JNEUROSCI.4438-13.2014","article-title":"Imaging light responses of foveal ganglion cells in the living macaque eye","volume":"34","author":"Yin","year":"2014","journal-title":"J Neurosci"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.exer.2011.03.006","article-title":"Optimization of laser-induced choroidal neovascularization in African green monkeys","volume":"92","author":"Goody","year":"2011","journal-title":"Exp Eye Res"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol Ther"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"309ra165","DOI":"10.1126\/scitranslmed.aac4882","article-title":"The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease","volume":"7","author":"Sidman","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/hum.2016.085","article-title":"Highly efficient delivery of adeno-associated viral vectors to the primate retina","volume":"27","author":"Boye","year":"2016","journal-title":"Hum Gene Ther"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"11072","DOI":"10.1128\/JVI.77.20.11072-11081.2003","article-title":"Identification of a heparin-binding motif on adeno-associated virus type 2 capsids","volume":"77","author":"Kern","year":"2003","journal-title":"J Virol"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1128\/JVI.77.12.6995-7006.2003","article-title":"Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding","volume":"77","author":"Opie","year":"2003","journal-title":"J Virol"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ymthe.2017.12.002","article-title":"AAV8-antiVEGFfab ocular gene transfer for neovascular age-related macular degeneration","volume":"26","author":"Liu","year":"2018","journal-title":"Mol Ther"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s004170050360","article-title":"Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate","volume":"238","author":"Cui","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.mam.2012.06.003","article-title":"Animal models of age related macular degeneration","volume":"33","author":"Pennesi","year":"2012","journal-title":"Mol Aspects Med"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/jcp.20525","article-title":"Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development","volume":"206","author":"Vinores","year":"2006","journal-title":"J Cell Physiol"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1038\/s41598-022-08492-7","article-title":"Evaluation of vascular endothelial growth factor (VEGF) level in the tears and serum of age-related macular degeneration patients","volume":"12","author":"Shahidatul-Adha","year":"2022","journal-title":"Sci Rep"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5214\/ans.0972.7531.220408","article-title":"Exploring the role of VEGF in Indian age-related macular degeneration","volume":"22","author":"Sharma","year":"2015","journal-title":"Ann Neurosci"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1006\/mvre.2002.2407","article-title":"Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes","volume":"64","author":"Otani","year":"2002","journal-title":"Microvasc Res"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmology"},{"key":"bib58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/a-1777-5033","article-title":"Importance of nonhuman primates as a model system for gene therapy development in ophthalmology","volume":"239","author":"Wozar","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/archophthalmol.2011.210","article-title":"Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates","volume":"129","author":"Nork","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"bib3","article-title":"Wet age-related macular degeneration (Wet AMD)","volume-title":"StatPearls","author":"Hobbs","year":"2022"},{"key":"bib59","first-page":"5055","article-title":"Interim results for the phase 1\/2 PRISM trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine for with neovascular (wet) age-related macular degeneration. Presented at the 41st Annual Meeting of the American Society of Retina Specialists","volume-title":"Invest Ophthalmol Vis Sci","author":"Kay","year":"2023"},{"key":"bib60","article-title":"First interim results (24 weeks) from the randomized phase 2 dose expansion stage of the PRISM clinical trial evaluating 4D-150 in high need patients with neovascular (wet) age-related macular degeneration","volume-title":"Presented at the Angiogenesis, Exudation, and Degeneration Symposium","author":"Khanani"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2802302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:46Z","timestamp":1791927106000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2802302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":61,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.65.14.1","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}